Back

MS4A4A modifies the risk of Alzheimer disease by regulating lipid metabolism and immune response in a unique microglia state

You, S.-F.; Brase, L.; Filipello, F.; Iyer, A.; Del-Aguila, J.; He, J.; Albanus, R.; Budde, J.; Norton, J.; Gentsch, J.; Dräger, N.; Sattler, S.; Kampmann, M.; Piccio, L.; Morris, J.; Perrin, R.; McDade, E.; Dominantly Inherited Alzheimer Network, ; Paul, S.; Cashikar, A.; Benitez, B.; Harari, O.; Karch, C. M.

2023-02-08 neurology
10.1101/2023.02.06.23285545 medRxiv
Show abstract

Genome-wide association studies (GWAS) have identified many modifiers of Alzheimer disease (AD) risk enriched in microglia. Two of these modifiers are common variants in the MS4A locus (rs1582763: protective and rs6591561: risk) and serve as major regulators of CSF sTREM2 levels. To understand their functional impact on AD, we used single nucleus transcriptomics to profile brains from carriers of these variants. We discovered a "chemokine" microglial subpopulation that is altered in MS4A variant carriers and for which MS4A4A is the major regulator. The protective variant increases MS4A4A expression and shifts the chemokine microglia subpopulation to an interferon state, while the risk variant suppresses MS4A4A expression and reduces this subpopulation of microglia. Our findings provide a mechanistic explanation for the AD variants in the MS4A locus. Further, they pave the way for future mechanistic studies of AD variants and potential therapeutic strategies for enhancing microglia resilience in AD pathogenesis.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.